The African Medicines Agency (AMA) has been established under the African Union to contribute to the improvement of access to medicines within the continent.

Benefit of AMA

• Support the growth of local pharmaceutical production, a key objective of the Pharmaceutical Manufacturing Plan for Africa (PMPA).
• Catalyzing trade in support of the Africa Continental Free Trade Area (AfCFTA).
• Allow the collaborate with NMRA in the identification of substandard and falsified medical products (SFs) and facilitate information sharing across countries.
• Enable expanded and timely access to effective, safe, and quality medicines for the treatment of priority diseases
• Allow NMRA to participate in joint reviews of clinical trial applications for vaccines and assessment of "highly complex" product dossiers such as biosimilars
• Allow access to the database for Active Pharmaceutical Ingredients (API) manufacturing sites.
• Allow more focused resources for value adding activities and making evidence based scientific regulatory decisions
• Allow for increased reliance based on harmonized regulatory requirements across Africa enabling acceleration and simplification of access to medicines;
• Allow for technical backup, worksharing, synergies and collaboration ultimately ensuring overall optimization of the healthcare system.